000			01721 a2200409 4500
005			20250517091754.0
264		0	_c20170117
008			201701s 0 0 eng d
022			_a1815-7920
024	7		_a10.5588/ijtld.15.0570 _2doi
040			_aNLM _beng _cNLM
100	1		_aJohnson, M G
245	0	0	_aMedium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements. _h[electronic resource]
260			_bThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _cMay 2016
300			_a600-4 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAntitubercular Agents _xtherapeutic use
650	0	4	_aBacteriological Techniques
650	0	4	_aClinical Trials, Phase II as Topic _xmethods
650	0	4	_aControlled Clinical Trials as Topic _xmethods
650	0	4	_aCulture Media
650	0	4	_aEndpoint Determination
650	0	4	_aHumans
650	0	4	_aMycobacterium tuberculosis _xdrug effects
650	0	4	_aPredictive Value of Tests
650	0	4	_aReproducibility of Results
650	0	4	_aSample Size
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aTuberculosis _xdiagnosis
700	1		_aStout, J E
700	1		_aBenator, D A
700	1		_aWhitworth, W C
700	1		_aHolland, D P
773	0		_tThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _gvol. 20 _gno. 5 _gp. 600-4
856	4	0	_uhttps://doi.org/10.5588/ijtld.15.0570 _zAvailable from publisher's website
999			_c25931522 _d25931522